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Introduction
In industrialized countries cardiovascular (CV) disease is the number one cause of death and CV prevention programs have been evolved. There is no longer doubt that patients with inflammatory joint diseases (IJD) have an increased risk of CV disease. Within the IJD group, patients with rheumatoid arthritis (RA) have been most extensively investigated concerning CV risk, 1 2 but the CV burden of patients with psoriatic arthritis (PsA) 3 4 and ankylosing spondylitis (AS) 5 6 has also been documented to be increased compared to the general population. RA is associated with the same risk of myocardial infarction as patients with diabetes mellitus. 1 In the latest European Society of Cardiology's (ESC) guidelines for CV disease prevention, 7 immunological diseases like RA is for the first time mentioned as a high risk factor. RA alone is not an indication for lipid lowering (LL) treatment, but is recommended to be taken into consideration as a part of the CV risk stratification.
For several decades the increased CV risk in IJD has been known, but this knowledge has not been implemented into clinical practice. There is still a lack of CV hard end point trials for this patient group, although some post hoc analyses from large placebo controlled trials with CV outcome have reported that patients with IJD have comparable cardio-protective effect of statins as those without IJD. 8 9 A multicenter audit recording CV risk in patients with RA and systemic lupus erythematosus concludes that CV risk factors are inadequately managed in these diseases. 10 Furthermore, Toms et al reported that there was a substantial undertreatment of CV risk in patients with RA. 11 Thus, there is an unmet need of systematic CV prevention in patients with IJD. We have initiated a preventive cardio-rheuma clinic for patients with IJD. The objective of this report is to evaluate the proportion of patients with IJD in need of CV prevention, and the clinical effects of the LL therapy with regard to achievement of guideline recommended lipid targets.
Patients and methods
Patients with IJD were referred for CV risk stratification from a rheumatology out patient clinic or from general practitioners, to the Preventive Cardio-Rheuma clinic during the period March 2009 and July 2012. Referral criteria were diagnosed IJD, age between 25 and 85 years and fulfilment of at least one of the following criteria: Known CV risk factor(s), symptoms/signs of a risk factor, familial premature CV disease or simply that a patient wished to undergo CV risk stratification. At the first consultation CV risk stratification was performed. The patient was classified to either primary or secondary CV prevention with LL treatment, or to have low risk with no indication for medical intervention. LL treatment was adjusted until at least two lipid targets were achieved (or at the nearest possible level of the lipid targets).
Recording of CV risk factors
When the patients received a letter regarding date/time for the consultation, they also received a CV questionnaire, which was completed and returned at the consultation. 
Follow up until treatment goals were reached
The cardiologist initiated the LL intervention with statins and continued or changed the LL treatment until at least two lipid targets were achieved (or at the nearest possible level of the lipid targets), before the patients were discharged for further follow up by the general practitioner.
Statistics
The data are presented as crude data and the results are expressed as mean±SD and median (IQR) for normally and non-normally distributed characteristics, respectively. The data were compared using paired samples t-test, ANOVA-, Kruskal-Wallis-and Ҳ 2 -tests as appropriate. Data analyses were performed using IBM SPSS V20.
Results

Patient characteristics
Four hundred and twenty six patients with IJD (RA n=257, AS n=108 and PsA n=61) were referred to the Preventive Cardio-Rheuma clinic (figure 1). Patients with RA were older than the other patient groups, p<0.001 (table 1) . The RA patients were mostly female (73.2%) and the majority of the AS patients were as expected men (68.5%). In the PsA patient group the gender distribution was more equal (female 55.7%). The median disease duration was about 15 years in patients with RA and PsA, but 22.5 years in AS patients. As expected, the PsA patients had a slightly higher body mass index (p=0.003). Approximately 6-10% of all the patients had established CV disease (RA 9.7%, AS 10.2%, PsA 6.6%) ( 
Cardiovascular risk stratification
Of the 426 patients, 270 were categorized to preventive LL treatment (63.4%) (figure 1). The proportions of patients having a SCORE >5% (categorized to primary prevention) were not similar across the patient groups (RA/AS/PsA: 13.6%/16.4%/14.3%, p=0.80). More than 3/4 (76.7%) of the patients in need of LL intervention had either CV disease, CP or both, and were categorized to secondary preventive treatment.
Treatment to target
Indication for LL intervention was found in approximately 60% of all the referred patients.
Initiation of LL treatment was done with statins (atorvastatin, simvastatin, rosuvastatin or pravastatin). Patients reaching at least two lipid targets were for RA 92.1%, AS 90.0%, and for PsA 82.9% (figure 2). In the combined IJD group, 40.4% reached all 4 lipid targets, 30.4% reached 3 lipid targets and 19.6% only obtained 2 of the targets. LL treatment was unsuccessful in 26 patients (9.6%) and there were various reasons for this. Two patients did not reach lipid targets at the highest possible dose of statins. Three patients did not reach lipid goals, but were so close to targets that the lipid profile was accepted by the cardiologist.
One patient had an unacceptable CK increase and two patients had a rise in the liver enzymes, and statin treatment was stopped. The increase in liver enzymes and CK was not >3 times upper normal limit. Five patients died (n=4 outside the hospital, n=1 of colon cancer with liver metastasis), one patient was diagnosed with lymphoma and was lost to follow up.
Nine patients preferred follow-ups by their general practitioner, one did not want to take statins and another patient did not obtain targets due to poor compliance. After a carotid endarterectomy, one patient was followed by the vascular surgery clinic at Oslo University Hospital, and was therefore lost to follow up at the Preventive Cardio-Rheuma clinic. Some patients did experience tolerable minor side effects like muscle tenderness or symptoms from the gastrointestinal tract. These were not recorded systematically in our clinical setting, if the statin treatment were not changed. There were no serious adverse events concerning statin medications. The patients needed on average less than 3 consultations to reach at least two lipid targets.
Lipid attainment in primary prevention
A total of 23.3% of the patients were in need of LL intervention and were categorized to primary prevention (figure 1). Baseline TC and LDL-c were higher in RA compared to AS and PsA (p=0.17 and p=0.11 respectively). Before the patients were discharged for further follow up by the general practitioner, the lipid profile were lower than or at target values in all patients, except for TG in PsA (table 2) . Twenty percent of the PsA patients, who were categorized to LL intervention, had combined dyslipidaemias, which includes elevated TG and low HDL-c levels. This may have influenced the incompleteness of reaching the TG targets. In the combined patient group; IJD, there was a significant change in all lipids from first to final consultation, except for HDL-c (figure 2). When evaluating the 3 patient groups separately, there was not a significant change in LDL-c in patients with PsA concerning primary prevention (table 2) . This may be a reflection of the low number of PsA patients (n=9). There was no significant change in TG levels among AS and PsA patients. As in the combined IJD group, HDL-c did not change significantly for RA, AS and PsA patients (table   2) . The proportion of patients categorized to primary prevention reaching each lipid target was for TC: 60.3%, LDL-c: 66.7%, HDL-c: 82.5% and TG: 69.8% (figure 3).
Lipid attainment in secondary prevention
Baseline lipids were lower in patients who had established CV disease and who were categorized to secondary preventive treatment, compared to patients categorized to primary prevention (table 2) . This was probably due to that some patients [RA n=8 (14.0%), AS n=7 (13.5%) and PsA n=8 (30.3%)] were already statin users when referred to the clinic, although the statin dosage was inadequate for reaching recommended lipid targets. These patients were also included into the analysis, because one of our aims was to evaluate whether attainment of lipid targets were possible. For all the patient groups, the final mean levels for LDL-c, HDL-c and TG were under or at goal values except for TC which were closely at target (table 2) . This was only so for patients with RA and was due to the higher HDL-c in this patient group. The percent change in lipids from first to final consultation was significant except for HDL-c, as in primary prevention, in the combined IJD group (figure 2) and for the separate patient groups; RA, AS and PsA ( 
Discussion
In 426 patients referred to CV risk stratification, more than 60% were in need of LL intervention. Of these, two thirds were categorized to intensive LL treatment and one third to primary prevention. The lipid targets were not reached in 10% of the patients. On average, only three consultations were needed to obtain 2 recommended lipid goals.
In the general population approximately 40% have been reported to obtain lipid targets. 15 16 This was to a great extent due to suboptimal use of LL treatment. There are several potential reasons for this unsuccessful result. Physicians may be concerned about possible side effects or that increasing statin doses only result in marginal LL effect, and there is the issue of compliance. In our report a very high proportion of the patients reached recommended goals, but over time this goal attainment may be lower. Future studies are warranted to reveal this. Lindhardsen et al also reported that physicians less often initiate secondary prevention in RA patients compared to non-RA patients, with statins being the most underused drugs. 17 A high number of our patients did not receive LL treatment at baseline despite established CV disease or asymptomatic CP. These patients have a very high risk for future fatal myocardial infarction. 7 18 Patients with IJD have a systemic inflammation and lower lipids compared to the general population. Hypothetically, the systemic inflammation may be a reason for the need of higher statin doses to obtain the same LL effect as the general population. Contradicting this is the lower lipid levels. These factors illuminate the difficulties in CV risk stratification and prevention in IJD patients. Recent published data indicates that the LL effect of statins in RA, AS and PsA patients are comparable to non-IJD patients. 9 19 Patients with IJD have a severe chronic and disabling disease, and for that reason often use several medications. Polypharmacy increases the risk of drug interactions, and may therefore potentially give more side effects. We did not observe this in our patients, which fall in line with the recently reported comparable side effects by statins in patients with
Formatted: Highlight and without IJD. 9 19 Although, the patients with IJD had somewhat more side effects from the gastro intestinal tract.
Our focus has been to evaluate the CV risk in IJD patients, and initiate optimal preventive treatment when needed in accordance with guidelines for the general population.
Ultrasound of the carotid arteries has been an important part of the risk stratification as we found that almost half of the patients had asymptomatic CP.
RA patients have a significantly shortened life expectancy, which is mainly due to CV disease. 20 21 The background inflammation is most likely an important reason for the substantially increased risk of CV disease in RA. Statins reduces the systemic inflammation in addition to the LL effect, [22] [23] [24] [25] and has been shown to reduce joint inflammation in RA. 26 Furthermore, statins may have a beneficial effect on endothelial function, 22 arterial stiffness 27 and in improving HDL-c anti-inflammatory properties in patients with RA. 28 A costeffectiveness analysis concludes that the dual effect of statins (LL and anti-inflammatory) makes this therapy highly cost effective in RA patients. 29 Hypothetically this would also apply for AS and PsA patients.
A placebo controlled study (TARA) showed that treatment with atorvastatin 40 mg resulted in a reduction in CRP and ESR, and a significant lower swollen joint count compared to placebo. 26 Due to our CV focus, swollen joint count was not recorded and thus we could not relate statins to disease activity. This is an observational report, and not as well controlled as experimental studies, which is an obvious limitation.
Strengths of our clinical data are the relatively large number of IJD patients and that all have been treated by the same physician. A further strength is that the 3 patient groups were comparable regarding CV risk factors.
In conclusion, more than 60% of IJD patients who were referred to CV risk stratification were in need of preventive treatment with statins, supporting the importance and relevance of establishing preventive cardio-rheuma clinics. Of these patients, 90% obtained lipid targets in less than three consultations. No serious adverse side effects were observed. Our data illustrate that LL medication as statins are effective and safe in patient with IJD. Longitudinal data are needed to demonstrate whether LL in patients with IJD also can reduce the risk of CV disease and outcome. %
